A randomized, open-label trial of telbivudine versus adefovir dipivoxil in adults With HBegAg [Hepatitis B e antigen]-positive, compensated chronic hepatitis B

Trial Profile

A randomized, open-label trial of telbivudine versus adefovir dipivoxil in adults With HBegAg [Hepatitis B e antigen]-positive, compensated chronic hepatitis B

Completed
Phase of Trial: Phase III

Latest Information Update: 15 May 2015

At a glance

  • Drugs Telbivudine (Primary) ; Adefovir dipivoxil
  • Indications Hepatitis B
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Idenix Pharmaceuticals; Merck Sharp & Dohme
  • Most Recent Events

    • 04 Dec 2007 Results have been published
    • 24 May 2007 Interim results have been reported at DDW.
    • 11 Dec 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top